

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/258921730>

GPER activates Notch signaling in breast cancer cells and cancer-associated fibroblasts (CAFs)

ARTICLE *in* THE INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY · NOVEMBER 2013

Impact Factor: 4.05 · DOI: 10.1016/j.biocel.2013.11.011 · Source: PubMed

CITATIONS

7

READS

66

5 AUTHORS, INCLUDING:



[Marco Pupo](#)

University of Geneva

11 PUBLICATIONS 201 CITATIONS

SEE PROFILE



[Sergio Abonante](#)

Università degli Studi di Perugia

31 PUBLICATIONS 302 CITATIONS

SEE PROFILE



[Anna Maria Musti](#)

Università della Calabria

38 PUBLICATIONS 2,698 CITATIONS

SEE PROFILE



Contents lists available at ScienceDirect

The International Journal of Biochemistry & Cell Biology

journal homepage: www.elsevier.com/locate/biocel

GPER activates Notch signaling in breast cancer cells and cancer-associated fibroblasts (CAFs)



Marco Pupo^a, Assunta Pisano^a, Sergio Abonante^b,
Marcello Maggiolini^{a,*}, Anna Maria Musti^{a,c,**}

^a Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy

^b Regional Hospital, Cosenza, Italy

^c Institute for Clinical Neurobiology, University of Würzburg, Würzburg, Germany

ARTICLE INFO

Article history:

Received 14 June 2013

Received in revised form 3 October 2013

Accepted 5 November 2013

Available online 22 November 2013

Keywords:

GPER

Estrogens signaling

Notch signaling

Breast cancer

Cancer-associated fibroblasts

ABSTRACT

The G protein-coupled receptor GPR30/GPER has been shown to mediate rapid effects of 17 β -estradiol (E2) in diverse types of cancer cells. Here, we provide evidence for a novel crosstalk between GPER and the Notch signaling pathway in breast cancer cells and cancer-associated fibroblasts (CAFs). We show that E2 and the GPER selective ligand G-1 induce both the γ -secretase-dependent activation of Notch-1 and the expression of the Notch target gene Hes-1. These inductions are prevented by knocking down GPER or by using a dominant-negative mutant of the Notch transcriptional co-activator Master-mind like-1 (DN-MAML-1), hence suggesting the involvement of GPER in the Notch-dependent transcription. By performing chromatin-immunoprecipitation experiments and luciferase assays, we also demonstrate that E2 and G-1 induce the recruitment of the intracellular domain of Notch-1 (NICD) to the Hes-1 promoter and the transactivation of a Hes-1-reporter gene, respectively. Functionally, the E2 and G-1-induced migration of breast cancer cells and CAFs is abolished in presence of the γ -secretase inhibitor GSI or DN-MAML-1, which both inhibit the Notch signaling pathway. In addition, we demonstrate that E2 and G-1 prevent the expression of VE-Cadherin, while both compounds induce the expression of Snail, a Notch target gene acting as a repressor of cadherins expression. Notably, both GSI and DN-MAML-1 abolish the up-regulation of Snail-1 by E2 and G-1, whereas the use of GSI rescues VE-Cadherin expression. Taken together, our results prove the involvement of the Notch signaling pathway in mediating the effects of estrogenic GPER signaling in breast cancer cells and CAFs.

© 2013 Elsevier Ltd. All rights reserved.

1. Introduction

Estrogens regulate critical signaling pathways involved in the control of cell proliferation and differentiation in reproductive and non-reproductive tissues (Liang and Shang, 2013). These steroids influence also the pathological processes of hormone-dependent tumors, like breast cancer, activating the estrogen receptor (ER) α and ER β which act as transcription factors binding to cognate the responsive elements located in the promoter regions of target genes (Ascenzi et al., 2006; Panno et al., 1996).

* Corresponding author at: Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. Tel.: +39 0984 493076; fax: +39 0984 493458.

** Corresponding author at: Institute for Clinical Neurobiology, University of Würzburg, D-97078 Würzburg, Germany. Tel.: +49 0931 201 44030; fax: +49 0931 201 44009.

E-mail addresses: marcellomaggiolini@yahoo.it (M. Maggiolini), E.Musti.A@klinik.uni-wuerzburg.de (A.M. Musti).

Although estrogens act mostly by this classic genomic mechanism, they are also able to rapidly activate transduction pathways in an ER-independent manner. In the last few years the membrane-associated G protein-coupled receptor GPR30/GPER has been widely shown to mediate signals triggered by estrogens, antiestrogens and phyto-xenoestrogens, including the quick MAPK activation, the induction of early gene expression, the proliferation and migration in different types of cancer cells (Albanito et al., 2007, 2008a,b; Chimento et al., 2012; De Marco et al., 2013; Filice et al., 2009; Lappano et al., 2010; Maggiolini et al., 2004; Pupo et al., 2012; Recchia et al., 2011; Santolla et al., 2012; Thomas et al., 2005; Vivacqua et al., 2006a,b, 2012). Moreover, the identification of synthetic molecules acting either as agonistic or antagonist ligands of GPER has extended our knowledge regarding the estrogenic GPER signaling (Bologa et al., 2006; Dennis et al., 2011; Lappano et al., 2012a,b; Rosano et al., 2012). Among these molecules, the GPER-agonist ligand G-1 has been shown to induce both gene expression changes and proliferation in diverse tumor cells. In this regard, several studies have shown that these effects mediated by ligand-activated GPER require a functional interaction with

the EGFR transduction pathway, the activation of the MAPK cascade, PI3K kinase and phospholipase C signaling (Maggiolini and Picard, 2010). Moreover, in ER-negative cancer cells like SkBr3 cells or cancer-associated fibroblasts (CAFs), GPER contributed to the stimulation of migration as its silencing drastically reduced the pro-migratory effects of 17 β -estradiol (E2) and G-1, which involved EGFR-dependent activation of one important GPER target gene named connective tissue growth factor (CTGF) (Madeo and Maggiolini, 2010; Pandey et al., 2009).

The Notch signaling and its crosstalk with several transduction pathways plays an important role in different aspects of breast cancer biology, including cell growth, EMT transition and cell migration (Guo et al., 2011). Notch consists of a family of single-pass transmembrane receptors (Notch1–4), which can be activated by the interaction with membrane-tethered ligands, including Dll (Delta-like 1–4) and Jagged (Jagged 1–2) (Miele, 2006). Up-regulated expression of Notch receptors and/or their ligands have been found in several human malignancies, including breast cancer (Al-Hussaini et al., 2011; Kopan and Ilagan, 2009). In addition, the expression of the Notch ligand Jagged-1 has been correlated with more aggressive malignant features (Reedijk et al., 2005). Upon ligand activation, Notch is cleaved by an ADAM metalloproteinase and γ -secretase and thereafter the membrane-released Notch intracellular domain (NICD) translocates to the nucleus (Guo et al., 2011). In the nucleus, NICD releases the expression of Notch target genes by recruiting transcriptional regulators, hence converting the RBP-J/CSL transcriptional repressor complex in a transcriptional activator (Yin et al., 2010). The most characterized transcriptional targets of Notch signaling are bHLH transcriptional repressors of the *Hes* (*Hes-1* to 7) and *Hey* (*Hey-1* and 2, L) subfamilies (Iso et al., 2003). Notch-induced activation of *Hes* and *Hey* genes play an important role in cell fate determination during organ development (Guo et al., 2011). Furthermore, Notch-dependent expression of *Hes* and *Hey* genes has been described in different types of cancer cells and correlates with Notch tumorigenic activities (Miele, 2006). An additional Notch-target gene is the zinc-finger transcriptional repressor *Snail*, which has been shown to trigger EMT by directly repressing E-cadherin expression (Wang et al., 2010). Notch-dependent up-regulation of *Snail* and the consequent E-cadherin repression represent the main pathway mediating the Notch-dependent migration in diverse tumor cells (Chen et al., 2010; Guo et al., 2011; Matsuno et al., 2012).

In the present study, we provide novel evidence showing that ligand-activated GPER triggers Notch activation and expression of Notch target genes. Moreover, we have assessed that Notch signaling contributes to GPER-mediated migration in ER-negative breast cancer cells and cancer-associated fibroblasts.

2. Materials and methods

2.1. Reagents

17 β -Estradiol (E2) was purchased from Sigma–Aldrich (Milan, Italy); γ -Secretase inhibitor cbz-Leu-Leu-Nle-CHO (GSI) and 1-[4-(6-bromobenzol[1,3]diodo-5-yl)-3a,4,5,9b-tetrahydro3H-cyclopenta[c]quinolin-8yl]-ethanone (G-1) were purchased from Calbiochem (Merck KGaA, Frankfurt, Germany); Notch ligand Jagged-1 (DSL Peptide 188–204) (JAG-1) was obtained from AnaSpec (DBA Milan, Italy). E2 was dissolved in ethanol while G-1, GSI and JAG-1 were solubilized in DMSO.

2.2. Cell cultures

The SkBr3 breast cancer cells were maintained in RPMI-1640 (Invitrogen, Gibco, Milan, Italy) without phenol red, supplemented

with 10% fetal bovine serum (FBS). MCF7 breast cancer cells were maintained in DMEM with phenol red supplemented with 10% FBS. Cells were switched to medium without serum the day before experiments for immunoblots, reverse transcription polymerase chain reaction (RT-PCR) and chromatin immunoprecipitation (ChIP). Both cell lines were grown in a 37 °C incubator with 5% CO₂. CAFs were extracted as previously described (Madeo and Maggiolini, 2010; Pupo et al., 2012, 2013) maintained in a mixture of MEDIUM 199 and HAM'S F-12 (1:1) supplemented with 10% FBS. Primary cells cultures of breast fibroblasts were characterized by immunofluorescence. Briefly cells were incubated with human anti-vimentin (V9) and human anti-cytokeratin 14 (LL001), all antibodies were from Santa Cruz Biotechnology, DBA (Milan, Italy). In order to assess fibroblasts activation, we used anti-fibroblast activated protein α (FAP α) antibody (H-56) purchased from Santa Cruz Biotechnology, DBA (Milan, Italy) (data not shown). We used CAFs passaged for up to five population doublings for the experiments performed using these cells. CAFs were also switched to medium without serum the day before experiments for immunoblots and reverse transcription polymerase chain reaction (RT-PCR)

2.3. Western blotting

Western blotting experiments were performed as previously described (Madeo et al., 2010). Briefly, cells were exposed to ligands, and then lysed in a buffer containing 1% SDS and a mixture of protease inhibitors. Equal amounts of whole protein extract were resolved on SDS-polyacrylamide gel, transferred to a nitrocellulose membrane (Amersham Biosciences, Milan, Italy), probed overnight at 4 °C with antibodies against *Hes-1* (H-140), *Notch-1* (C-20), *Snai1* (G-7), *VE-Cadherin* (N-14), *ER α* (F-10), *GPER* (N-15) and β -actin (C-2) purchased from Santa Cruz Biotechnology (DBA, Milan, Italy), and then revealed using the ECL[®] Western Blotting Analysis System (GE Healthcare, Milan, Italy). Results of densitometric analyses of Western blots, obtained using ImageJ software, are presented as optical density (OD; expressed in arbitrary units) relative to the control (β -actin).

2.4. Reverse transcription and quantitative RT-PCR

Total RNA was extracted using Trizol commercial kit (Invitrogen, Milan, Italy) according to the manufacturer's protocol. RNA was quantified spectrophotometrically and its quality was checked by electrophoresis through agarose gel stained with ethidium bromide. Only samples that were not degraded and showed clear 18S and 28S bands under ultraviolet light were used for real-time PCR. Total cDNA was synthesized from RNA by reverse transcription using the murine leukemia virus reverse transcriptase (Invitrogen, Milan, Italy) following the protocol provided by the manufacturer. The expression of selected genes was quantified by quantitative RT-PCR carried out as previously described (Maggiolini et al., 1999). *Hes-1*, *Notch-1*, *Snail*, *VE-cadherin* and the internal control *RPLP0* (also known as *36B4*) cDNAs yielded bands of 346, 289, 406, 319 and 408 bp with 21, 25, 22, 23 and 10 PCR cycles, respectively. The primers pairs used to amplify the fragments were: 5'-CCCAGCCAGTGTCAACACGAC-3' (forward) and 5'-ATTAACGCCCTCGCACGTGG-3' (reverse) for *Hes-1*; 5'-GCATAGTCCAAAAAGTCTCTG-3' (forward) and 5'-GTGCACTCTGGCATAACAC-3' (reverse) for *Notch-1*; 5'-CTCACCGGCTCCTTCGTCT-3' (forward) and 5'-ACACGCTGGCACTGGTACT-3' (reverse) for *Snail*; 5'-TCTCCGAATAGACAAGGAC-3' (forward) and 5'-AGTAAGATGGCTACCACTGC-3' (reverse) for *VE-Cadherin*; 5'-CTCAACATCTCCCCCTTCTC-3' (forward) and 5'-CAAATCCCATATCCTCGTCC-3' (reverse) for *RPLP0*. Results of densitometric analyses of blots,

obtained using ImageJ software, are presented as optical density (OD; expressed in arbitrary units) relative to the control (*RPLP0*).

2.5. Real-time PCR

Gene expression was evaluated also by real-time PCR as we previously described (Lappano et al., 2011). For *Hes-1*, *Snail*, *VE-Cadherin*, and the ribosomal protein *18S*, which was used as a control gene to obtain normalized values, the primers were: 5'-TCAACACGACACCGGATAAA-3' (*Hes-1* forward) and 5'-CCGCGAGCTATCTTTCTTCA-3' (*Hes-1* reverse); 5'-CTTCCAGCAGC-CCTACGAC-3' (*Snail* forward) and 5'-CGGTGGGGTTGAGGATCT-3' (*Snail* reverse); 5'-TTTCCAGCAGCCTTCTACCA-3' (*VE-Cadherin* forward) and 5'-GGAAGAAGTGGCCCTGTCA-3' (*VE-Cadherin* reverse) and 5'-GGCGTCCCCCAACTTCTTA-3' (*18S* forward) and 5'-GGGCATCACAGACCTGTATT-3' (*18S* reverse), respectively.

2.6. Chromatin Immunoprecipitation (ChIP) assay

Cells were grown in 10-cm plates and then exposed to ligands for 8 h. Thereafter, cells were cross-linked with 1% formaldehyde and sonicated. Supernatants were immunocleared with sonicated salmon DNA/protein A agarose (Upstate Biotechnology, Inc., Lake Placid, NY) and immunoprecipitated with the anti-*Notch-1* (C-20) antibody or non specific IgG (Santa Cruz Biotechnology, DBA, Milan, Italy). Pellets were washed, eluted with a buffer consisting of 1% SDS and 0.1 mol/L NaHCO₃, and digested with proteinase K. DNA was obtained by phenol/chloroform extraction and precipitated with ethanol. A 4 µl volume of each sample was used as template to amplify by real-time PCR a RBP-J binding site corresponding to -167 to +6 located in the 5'-flanking region of *Hes-1* gene. The primers used were Fwd: 5'-CAGACCTTGTCCTGGCG-3' and Rev: 5'-TGATGCCCTAGGCCCTG-3'. Data were normalized with respect to unprocessed lysates (input DNA). Inputs DNA quantification was performed by using 4 µl of the template DNA. The relative antibody-bound fractions were normalized to a calibrator that was chosen to be the basal, untreated sample. Final results were expressed as percent differences with respect to the relative inputs.

2.7. Plasmids

The luciferase reporter plasmid *Hes1-Luc* (-467 to +46 of the *Hes1* promoter with the luciferase gene) was a kind gift from Dr. Hee-Sae Park (Hormone Research Center, School of Biological Sciences and Technology, Chonnam National University, Yongbong-dong, Buk-ku, Gwangju, Republic of Korea). The plasmid encoding dominant-negative MAML-1 (DN-MAML-1) was a gift from Dr. M. Bocchetta (Cardinal Bernardin Cancer Center, Loyola University Chicago, Illinois, USA). The Sure Silencing (sh) ERα and the respective control plasmid (shRNA), generated in pGeneClip Puromycin Vector, were purchased from SA Bioscience Corp. (Frederick, MD, USA) and used according to the manufacturer's recommendations. Short hairpin RNA construct against human GPER (shGPR30/shGPER) and the unrelated shRNA control construct were previously described (Pandey et al., 2009).

2.8. Transfection, luciferase assays and gene silencing experiments

For luciferase assays, cells were plated into 24-well plates with 500 µl of regular growth medium/well the day before transfection. Cell medium was replaced with medium supplemented with 1% charcoal-stripped (CS) FBS lacking phenol red and serum on the day of transfection, which was performed using the X-treme Gene 9 reagent as recommended by the manufacturer (Roche Diagnostics, Milan, Italy) with a mixture containing 0.5 µg of reporter

plasmid and 2 ng of pRL-TK. After 5–6 h, ligands were added and cells were incubated for 24 h. Luciferase activity was then measured using the Dual Luciferase Kit (Promega, Milan, Italy) according to the manufacturer's recommendations. Firefly luciferase activity was normalized to the internal transfection control provided by the Renilla luciferase activity. The normalized relative light unit values obtained from cells treated with vehicle were set as one-fold induction upon which the activity induced by treatments was calculated. For the gene silencing experiments, cells were plated into 10-cm dishes, transfected in serum-free medium for 24 h before treatments using X-treme Gene 9 (Roche Diagnostics, Milan, Italy), according to the manufacturer's recommendations with shRNA, shGPER, shERα, DN MAML-1 and the unrelated empty vector.

2.9. Wound-healing assay

SkBr3 cells and CAFs were seeded into 12-well plates in regular growth medium. When at 70–80% confluence, the cells were washed once and medium was replaced with 2.5% charcoal-stripped FBS. Cells were then pre-treated with GSI and treated with E2, G-1 and JAG-1. Then, a p200 pipette tip was used to scratch the cell monolayer. We evaluated cell migration in three independent experiments after 24 h of treatment; data are expressed as a percentage of cells in the wound area upon treatment compared with cells receiving vehicle.

2.10. Transwell cell migration assay

Migration assays were performed with SkBr3 cells and CAFs in triplicate using Boyden chambers (Costar Transwell, 8 mm polycarbonate membrane). For knockdown experiments, cells were transfected with the plasmid DN-MAML1 or with an empty vector construct using X-treme Gene 9 reagent in medium without serum. After 24 h, cells were seeded in the upper chambers. Treatments were added to the medium without serum in the bottom wells. After 24 h, cells on the bottom side of the membrane were fixed, stained with GIEMSA (Sigma-Aldrich Milan, Italy), photographed and counted.

2.11. Statistical analysis

Statistical analysis was performed using analysis of variance followed by Newman-Keuls testing to determine differences in means. *p*-Values < 0.05 are considered statistically significant.

3. Results

3.1. E2 and G-1 induce Notch-dependent expression of *Hes-1*

In order to investigate a possible functional interaction between GPER and Notch signaling, we first investigated whether ligand-activated GPER triggers Notch-dependent transcription. Hence, we evaluated the *Hes-1* mRNA expression in SkBr3 cells treated with E2, G-1 or the soluble Notch ligand JAG-1. As shown in Fig. 1A and B and in Supplementary Fig. 1A, all three ligands induced the levels of *Hes-1* particularly upon 24 h treatments. To assess the direct involvement of GPER in the up-regulation of *Hes-1*, we transfected SkBr3 cells with a shGPER which abrogated the expression of *Hes-1* induced by E2 and G-1 (Fig. 1C–F and Supplementary Fig. 1B). In contrast, in SkBr3 cells transfected with the shGPER and exposed to JAG-1, the induction of *Hes-1* was still evident (Fig. 1E and F and Supplementary Fig. 1B). To confirm the Notch-dependent up-regulation of *Hes-1* by E2 and G-1, we used the γ -secretase inhibitor named GSI which impaired the *Hes-1* response to these treatments along that promoted by JAG-1 as expected (Fig. 1G and H and




Fig. 1. Ligand-activated GPER induces the Notch-dependent expression of *Hes-1* mRNA in SkBr3 breast cancer cells. (A) mRNA expression of *Hes-1* in SkBr3 cells treated with 100 nM E2, 1 μM G-1 and 1 μM JAG-1, as indicated. (B) Densitometric analysis of *Hes-1* mRNA expressions normalized to *RPLP0*. (C) Immunoblots of GPER expression in SkBr3 cells transfected for 48 h with shRNA or shGPER. (D) Densitometric analysis of GPER expressions normalized to β-actin. (E) Expression of *Hes-1* mRNA in SkBr3 cells transfected with shRNA or shGPER for 24 h and then treated with 100 nM E2, 1 μM G-1 and 1 μM JAG-1 for additional 24 h. (F) Densitometric analysis of *Hes-1* mRNA expressions normalized to *RPLP0*. (G) mRNA expression of *Hes-1* in SkBr3 cells treated for 24 h with 100 nM E2, 1 μM G-1 and 1 μM JAG-1 alone or in combination with 100 nM of γ-secretase inhibitor (GSI). (H) Densitometric analysis of *Hes-1* mRNA expressions normalized to *RPLP0*. (I) mRNA expression of *Hes-1* in SkBr3 cells transfected for 24 h with an empty vector or a dominant-negative mutant of the Master-mind like 1 (DN-MAML-1) and then treated for additional 24 h with 100 nM E2, 1 μM G-1 and 1 μM JAG-1. (J) Densitometric analysis of *Hes-1* mRNA expressions normalized to *RPLP0*. Columns represent the mean ± SD of three independent experiments. (○), (●) and (□) indicate $P < 0.05$ for cells receiving vehicle (–) versus treatments. In panel D, (○) indicates $P < 0.05$ for cells transfected with shRNA respect to cells transfected with shGPER




Fig. 2. Ligand-activated GPER induced the Notch-dependent expression of *Hes-1* at protein level in SkBr3 breast cancer cells. (A) Immunoblots of *Hes-1* protein expression in SkBr3 cells transfected for 24 h with a shRNA or shGPER and then treated for additional 24 h with 100 nM E2, 1 μ M G-1 and 1 μ M JAG-1. (B) Densitometric analysis of *Hes-1* protein expressions normalized to β -actin. (C) *Hes-1* protein expression in SkBr3 cells treated for 24 hours with 100 nM E2, 1 μ M G-1 and 1 μ M JAG-1 alone or in combination with 100 nM of γ -secretase inhibitor (GSI). (D) Densitometric analysis of *Hes-1* protein expressions normalized to β -actin. (E) *Hes-1* protein expression in SkBr3 cells transfected for 24 h with an empty vector or a dominant-negative mutant of the Master-mind like 1 (DN-MAML-1) and then treated for additional 24 h with 100 nM E2, 1 μ M G-1 and 1 μ M JAG-1. (F) Densitometric analysis of *Hes-1* protein expressions normalized to β -actin. Columns represent the mean \pm SD of three independent experiments. (○) and (●) indicate $P < 0.05$ for cells receiving vehicle (–) versus treatments.

Supplementary Fig. 1C). In order to corroborate these results, we transfected SkBr3 cells with a dominant-negative mutant of the Master-mind like 1 (DN-MAML-1), which is a transcriptional co-activator of Notch-1 (Guo et al., 2011). As shown in Fig. 1I and J and in Supplementary Fig. 1D, the induction of *Hes1* mRNA by E2, G-1 and JAG-1 was no longer observed in presence of DN-MAML-1. To confirm these findings, we also evaluated *Hes-1* protein levels by western blot analysis. As shown in Fig. 2A–F, we found in all treatments described above, variations of *Hes-1* protein which reflected those of mRNAs.

Next, to corroborate the role elicited by GPER in mediating the Notch dependent transcription of *Hes-1*, upon E2 and G-1 treatments, we evaluated the expression of *Hes-1* mRNA also using the ER-positive MCF-7 breast cancer cells (Supplementary Fig. 2A–H). As previous reports have shown that in ER-positive breast cancer cells low doses of E2 may inhibit Notch activity (Rizzo et al., 2008a), we evaluated the expression of *Hes-1* mRNA by increasing

concentrations of E2 in both MCF-7 (ER-positive) and SkBr3 (ER-negative) breast cancer cells. As shown in Supplementary Fig. 3A–C, in SkBr3 cells, E2 induces the expression of *Hes-1* mRNA already at concentration of 1 nM. In contrast, in MCF-7 cells the expression of *Hes-1* mRNA was up-regulated only at higher concentrations of E2 (Supplementary Fig. 3D–F). Moreover, ER α silencing by shER α had no effect on the up-regulation of *Hes-1* mRNA by E2 (Supplementary Fig. 3G–K).

3.2. E2 and G-1 induce Notch activation and the recruitment of N1ICD to the *Hes-1* promoter sequence

Having established that E2 and G-1 trigger *Hes-1* expression in a GSI dependent fashion, we then verified whether these ligands induce the γ -secretase-mediated release of Notch intracellular domain (N1ICD), which is a hallmark of Notch activation. As shown in Fig. 3A and B, both E2 and G-1 along with JAG-1 stimulated the




Fig. 3. Ligand-activated GPER up-regulates the expression of both N1ICD and *Notch-1* in SkBr3 breast cancer cells. (A) N1ICD protein expression in SkBr3 cells treated for 24 h with 100 nM E2, 1 μM G-1 and 1 μM JAG-1 alone or in combination with 100 nM of γ -secretase inhibitor (GSI). (B) Densitometric analysis of N1ICD protein expressions normalized to β -actin. (C) N1ICD protein expression in SkBr3 cells transfected for 24 h with a shRNA or shGPER and then treated for additional 24 hours with 100 nM E2, 1 μM G-1 and 1 μM JAG-1. (D) Densitometric analysis of N1ICD protein expressions normalized to β -actin. (E) mRNA expression of *Notch-1* in SkBr3 cells treated with 100 nM E2 and 1 μM G-1, as indicated. (F) Densitometric analysis of *Notch-1* mRNA expressions normalized to *RPLP0*. (G) *Notch-1* full length (*Notch-1 FL*) protein expression in SkBr3 cells treated for 8 h with 100 nM E2 and 1 μM G-1. (H) Densitometric analysis of *Notch-1 FL* protein expressions normalized to β -actin. Columns represent the mean \pm SD of three independent experiments. (○) and (●) indicate $P < 0.05$ for cells receiving vehicle (–) versus treatments.

membrane-release of N1ICD in a GSI-sensitive manner. In addition, the abrogation of GPER expression by shGPER abolished only the membrane-release of N1ICD induced by E2 and G-1 (Fig. 3C and D), suggesting that GPER ligands trigger Notch activation.

As SkBr3 cells express constitutive levels of JAG-1 (data not shown), we asked whether the effects of E2 and G-1 on Notch activation could rely on the up-regulation of *Notch-1* expression. As shown in Fig. 3E–H, we found that E2 and G-1 induced both

mRNA and protein levels of *Notch-1*, further supporting the aforementioned data.

Performing ChIP experiments in SkBr3 cells, we next determined that E2 and G-1 together with JAG-1 induce in a GSI dependent fashion the recruitment of N1ICD to the RBP-J/CSL binding site located within the *Hes-1* promoter sequence (Fig. 4A). In accordance with these results, the transactivation of a *Hes-1* promoter reporter gene induced by E2, G-1 and JAG-1 was no longer evident in




Fig. 4. Ligand-activated GPER induces both the recruitment of N1ICD to *Hes-1* promoter and the transactivation of a *Hes-1* promoter reporter gene in SkBr3 cells. (A) The recruitment of N1ICD to the RBP-J site located within the *Hes-1* promoter induced in SkBr3 cells treated for 8 h with 100 nM E2, 1 μ M G-1 and 1 μ M JAG-1 was abolished treating cells also with 100 nM of γ -secretase inhibitor (GSI). The amplified sequences were evaluated by real-time PCR. Bar graphs show the mean \pm SD of three independent experiments. (B) SkBr3 cells were transfected with a *Hes-1* promoter reporter gene plasmid and then treated for 24 h with 100 nM E2, 1 μ M G-1 and 1 μ M JAG-1 alone or in combination with 100 nM GSI. The luciferase activities were normalized to the internal transfection control, and values of cells receiving vehicle (–) were set as 1-fold induction upon which the activity induced by treatments was calculated. Bar graphs represent the mean \pm SD of three independent experiments each performed in triplicate. (○) indicates $P < 0.05$ for cells receiving vehicle (–) versus treatments.

presence of GSI (Fig. 4B). Taken together, these results suggest that ligand-activated GPER triggers the expression of the Notch target gene *Hes-1* by inducing *Notch-1* expression, the membrane-release of N1ICD which is consequently recruited to the *Hes-1* promoter sequence.

3.3. Notch signaling is involved in the migration of SkBr3 cells induced by E2 and G-1

In order to address the biological response to Notch activation upon E2 and G-1 treatment, we evaluated the effects of Notch




Fig. 5. Inhibition of Notch signaling abrogates the migration of SkBr3 cells induced by E2, G-1 and JAG-1. The migration of SkBr3 cells evaluated by wound-healing (A) and Boyden chamber assays (B) upon exposure to 100 nM E2, 1 μ M G-1 and 1 μ M JAG-1 for 24 h was abolished in presence of 100 nM of γ -secretase inhibitor (GSI). The migration of SkBr3 cells evaluated by Boyden chamber assays (C) upon exposure to 100 nM E2, 1 μ M G-1 and 1 μ M JAG-1 for 24 h was abolished transfecting cells with a dominant-negative mutant of the Master-mind like 1 (DN-MAML-1). The migratory effects stimulated by E2 and G-1 were abrogated transfecting cells with shGPER (D). Columns show mean of three independent experiments done in triplicate and standardized to cells receiving vehicle (–), bars represent SD. (○) indicates $P < 0.05$ for cells receiving vehicle (–) versus treatments.




Fig. 6. Notch signaling is required for up-regulation of *Snail* and inhibition of *VE-Cadherin* expression in SkBr3 cells. (A) The up-regulation of the *Snail* mRNA expression induced in SkBr3 cells by a 24 h exposure to 100 nM E2, 1 µM G-1 and 1 µM JAG-1 was abolished transfecting cells for 24 h with a dominant-negative mutant of the Mastermind like 1 (DN-MAML-1) before treatments. (B) Densitometric analysis of *Snail* mRNA expressions normalized to *RPLP0*. (C) The induction of the *Snail* protein expression stimulated in SkBr3 cells by a 24 hours treatment with 100 nM E2, 1 µM G-1 and 1 µM JAG-1 was abrogated transfecting cells for 24 h with a dominant-negative mutant of the Mastermind like 1 (DN-MAML-1) before treatments. (D) Densitometric analysis of *Snail* protein expressions normalized to β-actin. (E) The down-regulation of *VE-Cadherin* mRNA expression in SkBr3 cells treated for 24 h with 100 nM E2, 1 µM G-1 and 1 µM JAG-1 was rescued treating cells with 100 nM of the γ-secretase inhibitor (GSI). (F) Densitometric analysis of *VE-Cadherin* mRNA expressions normalized to *RPLP0*. (G) The reduction of *VE-Cadherin* protein expression in SkBr3 cells treated for 24 h with 100 nM E2, 1 µM G-1 and 1 µM JAG-1 was prevented treating cells with 100 nM of the γ-secretase inhibitor (GSI). (H) Densitometric analysis of *VE-Cadherin* protein expressions normalized to β-actin. Columns represent the mean ± SD of three independent experiments. (○) indicates $P < 0.05$ for cells receiving vehicle (-) versus treatments.


signaling in the migration of SkBr3 cells. As determined by wound-healing assays, the migration of SkBr3 cells induced by E2 and G-1 as well as JAG-1 was abolished using GSI (Fig. 5A and Supplementary Fig. 4). Performing Boyden chamber assays, we confirmed the aforementioned results (Fig. 5B and Supplementary Fig. 5A) and we demonstrated that the migration induced by E2, G-1 or JAG-1 is also prevented in SkBr3 cells transfected with DN-MAML-1 (Fig. 5C and Supplementary Fig. 5B). Moreover, shGPER transfection abolished SkBr3 migration induced by E2 and G-1, whereas JAG-1-induced migration was not affected (Fig. 5D and Supplementary Fig. 6).

Taken together, these data suggest that GPER and Notch signaling pathways are involved in the migration of SkBr3 cells stimulated by E2 and G-1.

3.4. E2 and G-1 up-regulate *Snail* and inhibit *VE-Cadherin* expression through the Notch signaling

In different types of cancer cells, the Notch-target gene *Snail* has been shown to repress the expression of cell-cell adhesion molecules, including E-cadherins and vascular endothelial

CAFs



(VE)-cadherin. In this regard, it has been shown that these genes are involved in the epithelial to mesenchymal transition (EMT) which is a biological process regulated by a network of transduction pathways including Notch signaling (Grego-Bessa et al., 2004). Hence, we investigated whether E2 and G-1 induced the expression of *Snail* at both mRNA and protein levels in a Notch-dependent manner. As shown in Fig. 6A–D and in Supplementary Fig. 7A, we found that E2 and G-1, as well as JAG-1, induced the expression of *Snail* which was abrogated by co-expression of DN-MAML-1. Next, we investigated whether the up-regulation of *Snail* by E2 and G-1 is coupled to an altered expression of cell-cell adhesion molecules. As SkBr3 cells lack *E-Cadherin* expression (Hiraguri et al., 1998), we evaluated the response of *VE-Cadherin*, which is expressed in SkBr3 cells (Endo et al., 2008). As shown in Fig. 6E–H and in Supplementary Fig. 7B, E2 and G-1 reduced the expression of *VE-Cadherin* at both mRNA and protein levels, in a GSI-sensitive fashion.

3.5. The GPER and Notch pathways cooperate in cancer-associated fibroblasts (CAFs)

Given the relevant contribution of the microenvironment to cancer cell growth and invasiveness (Kalluri and Zeisberg, 2006), we examined whether the cross-talk between Notch and GPER signaling pathways occurs in CAFs which play a pivotal role in the functional interaction between stroma and cancer cells toward tumor progression. Hence, we determined that GPER mediates the mRNA and protein expression of *Hes-1* induced by E2 and G-1 in CAFs obtained from breast cancer patients, whereas the *Hes-1* response to JAG-1 was not altered transfecting cells with a shGPER (Fig. 7A–F). Using GSI, the up-regulation of *Hes-1*, at both mRNA and protein levels, triggered by all agents was no longer observed (Fig. 7G–J). As biological counterpart, the migration of CAFs stimulated by E2, G-1 and JAG-1 was abolished using GSI, as assessed performing both wound-healing and Boyden chamber assays (Fig. 8A and B, Supplementary Figs. 8 and 9). Collectively, these data confirmed the results obtained in breast cancer cells and extended the potential of E2 and G-1 to engage the Notch signaling through GPER in main components of the tumor microenvironment like CAFs

4. Discussion

A wide number of studies have shown that the functional interactions among steroid receptors and growth factor receptors play a crucial role toward breast cancer progression (Bartella et al., 2012; Lappano et al., 2013; Vivacqua et al., 2009). In this regard, the estrogen action mediated by GPER via EGFR activation has made clear that GPER may facilitate the response to estrogens independently of the classical ERs. Accordingly, the functional cross-talk between GPER and EGFR has been documented in different types of malignancies and involved in relevant biological outcomes like the proliferation and migration of cancer cells (Maggiolini and Picard, 2010).

On the other side, deregulation of the Notch pathway by oncogenic signaling represents a further crossroad in tumor growth and




Fig. 8. Inhibition of Notch signaling abolishes the migratory effects stimulated by E2, G-1 and JAG-1 in CAFs. (A) Wound-healing and (B) Boyden chamber assays performed in CAFs to evaluate the migration in presence of 100 nM E2, 1 µM G-1 and 1 µM JAG-1 alone or in combination with 100 nM of the γ -secretase inhibitor (GSI). Bar graphs show representative experiments with means of triplicate samples. Results were standardized to data of cells receiving vehicle which were set to 100%. (○) indicates $P < 0.05$ for cells receiving vehicle (–) versus treatments.

invasion (Guo et al., 2011; Rizzo et al., 2008a). In particular, the Notch interaction with ER-mediated signaling as well as growth factor receptors has been shown in breast cancer cells (Al-Hussaini et al., 2011; Guo et al., 2011; Osipo et al., 2008; Rizzo et al., 2008b). Therefore, the response of breast cancer cells to estrogens may be dependent on the repertoire of receptors expressed in different cell contexts and the downstream transduction pathways that functionally cooperate toward tumor progression.

In the present study, we have used the ER-negative SkBr3 breast cancer cells in order to evaluate in a peculiar model system the potential cross talk between the Notch pathway and the GPER signaling. Worthy, we provide novel evidence showing that ligand-activated GPER triggers Notch-mediated gene expression changes and biological responses as cell migration. These findings were confirmed in CAFs derived from breast cancer patients, suggesting that the GPER/Notch signaling may be engaged by estrogens also in the tumor microenvironment that mainly contribute to tumor development (Kalluri and Zeisberg, 2006).

Fig. 7. Ligand-activated GPER induces *Hes-1* expression in CAFs. (A) Evaluation of *Hes-1* mRNA expression in CAFs transfected for 24 h with a shRNA or shGPER and treated for 8 h with 100 nM E2, 1 µM G-1 and 1 µM JAG-1. (B) Densitometric analysis of *Hes-1* mRNA expressions normalized to *RPLPO*. (C) Immunoblots of *Hes-1* protein expression in CAFs transfected for 24 h with a shRNA or shGPER and then treated for additional 18 h with 100 nM E2, 1 µM G-1 and 1 µM JAG-1. (D) Densitometric analysis of *Hes-1* protein expressions normalized to β -actin. (E) Immunoblots of GPER expression in CAFs transfected for 48 h with shRNA or shGPER. (F) Densitometric analysis of GPER expressions normalized to β -actin. (G) Evaluation of *Hes-1* mRNA expression in CAFs treated for 8 h with 100 nM E2, 1 µM G-1 and 1 µM JAG-1 alone or in combination with 100 nM of the γ -secretase inhibitor (GSI). (H) Densitometric analysis of *Hes-1* mRNA expressions normalized to *RPLPO*. (I) *Hes-1* protein expression in CAFs treated for 8 h with 100 nM E2, 1 µM G-1 and 1 µM JAG-1 alone or in combination with 100 nM of γ -secretase inhibitor (GSI). (J) Densitometric analysis of *Hes-1* protein expressions normalized to β -actin. Columns represent the mean \pm SD of three independent experiments. (○) and (●) indicate $P < 0.05$ for cells receiving vehicle (–) versus treatments. In panel F, (○) indicates $P < 0.05$ for cells transfected with shRNA respect to cells transfected with shGPER.

As the activation of the Notch transduction pathway induces the nuclear translocation of N1ICD and the transactivation of Notch-target genes (Miele, 2006), we initially assessed whether the ligand-activated GPER could stimulate the expression of one main Notch-regulated gene like *Hes-1*. Three independent lines of evidence support that indeed this is the case: (i) E2 and the selective GPER ligand G-1 increased the mRNA levels of *Hes-1*, (ii) E2 and G-1 triggered both the release of the Notch-1 intracellular domain (N1ICD) and its recruitments to the *Hes-1* promoter sequence, (iii) E2 and G-1 transactivated the *Hes-1* promoter, hence recapitulating the aforementioned findings. Notably, *Hes-1* up regulation by E2 or G-1 was confirmed also in ER-positive MCF-7 cells. Interestingly, our results (see Supplementary Fig. 3) show that high doses of E2 (100 nM) were necessary to induce *Hes-1* expression in MCF-7 cells, whereas *Hes-1* induction was already achieved at low dosage of E2 (1 nM) in SkBr3 cells. Moreover, we found that knock-down of ER α expression had no effect on *Hes-1* up-regulation in MCF-7 cells, whereas GPER silencing completely abrogated *Hes-1* up-regulation by E2 or G-1. These results indicate that ER-positive and ER-negative breast cancer cells have a different dose-response to E2, presumably relying on the different binding affinity of E2 for ER α and GPER, as demonstrated in previous studies (Revankar et al., 2005; Thomas et al., 2005). Importantly, the dose response curve of E2 on *Hes-1* expression in MCF-7 cells overcomes the apparent discrepancy between our data and the previous study by Rizzo and colleagues, showing that low doses of E2 reduce Delta-dependent activation of Notch signaling (Rizzo et al., 2008b).

The ability of E2 and G-1 to trigger Notch-dependent transcription was clearly demonstrated by the evidence that the up-regulation of *Hes-1* was abolished by using both GSI or DN-MAML-1, a dominant-negative mutant of Master-mind like 1, which is a Notch-1 transcriptional co-activator (Wu and Griffin, 2004). Likewise, the knockdown of GPER abrogated both the induction of *Hes-1* and the release of N1ICD upon E2 and G-1 treatments, hence demonstrating the involvement of GPER in the activation of Notch signaling by these ligands.

The mechanism through which GPER leads to *Notch-1* activation seems to be transcriptional, as an increase of *Notch-1* mRNA levels was found in response to E2 and G-1. Remarkably, this increase preceded the induction of the *Hes-1* mRNA levels (see Figs. 1A, B and 3E, F), suggesting that the deregulation of Notch-1 expression mediates the effects elicited by GPER on both Notch activation and Notch-dependent transcription. Conversely, in SkBr3 cells the constitutive JAGGED-1 expression was not altered by E2 and G-1 (data not shown), indicating that the boost of Notch induced by E2 and G-1 is sufficient to activate the Notch signaling. Accordingly, it has been reported that high *Notch-1* levels are associated with a poor prognosis in breast cancer (Al-Hussaini et al., 2011). Although the molecular mechanisms involved in the induction of Notch-1 by GPER remain to be fully elucidated, the cross talk between GPER and EGFR may be ruled out, as the inhibition of EGFR does not interfere with the up-regulation of *Hes-1* induced by E2 or G-1 (our published data). In this regard, further studies are required to investigate whether GPER may trigger the expression of Notch-1 through other transduction mechanisms.

The aforementioned findings were recapitulated and further highlighted by evaluating the role of Notch in a relevant biological response like cell migration. Of note, the ability of E2 and G-1 to stimulate the migration of SkBr3 cells was abolished using GSI or DM-MALM-1, hence indicating that both Notch activation and Notch-dependent transcription contribute to the migratory effects elicited by E2 and G-1.

The invasive and migratory ability of cancer cells have been previously associated with EMT (Matsuno et al., 2012; Thiery, 2002), that particularly in breast tumor involved the deregulation of E-cadherin expression through Notch and its target gene *Snail* (Wang

et al., 2010) In this regard, the up-regulation of *Snail* coupled to an altered expression of *VE-cadherin* induced by E2 and G-1 in a GSI-dependent fashion, further corroborates the contribution of the Notch-dependent transcription in cell migration and EMT triggered by these ligands.

Our results demonstrate for the first time that estrogen-activated GPER engages Notch signaling toward gene expression changes and biological responses in breast tumor cells and CAFs, hence providing a further mechanism through which estrogens may stimulate the progression of breast cancer.

Acknowledgements

This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC, project n.12849/2012), AIRC project Calabria 2011 and Fondazione Cassa di Risparmio di Calabria e Lucania.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.biocel.2013.11.011>.

References

- Albanito L, Lappano R, Madeo A, Chimento A, Prossnitz ER, Cappello AR, et al. G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells. *Environ Health Perspect* 2008a;116:1648–55.
- Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpio A, et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17 β -estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. *Cancer Res* 2007;67:1859–66.
- Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, Madeo A, et al. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. *Endocrinology* 2008b;149:3799–808.
- Al-Hussaini H, Subramanyam D, Reedijk M, Sridhar SS. Notch signaling pathway as a therapeutic target in breast cancer. *Mol Cancer Ther* 2011;10:9–15.
- Ascenzi P, Bocedi A, Marino M. Structure–function relationship of estrogen receptor alpha and beta: impact on human health. *Mol Aspects Med* 2006;27:299–402.
- Bartella V, De Marco P, Malaguarnera R, Belfiore A, Maggolini M. New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signaling in cancer. *Cell Signal* 2012;24:1515–21.
- Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. *Nat Chem Biol* 2006;2:207–12.
- Chen J, Imanaka N, Chen J, Griffin JD. Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. *Br J Cancer* 2010;102:351–60.
- Chimento A, Sirianni R, Casaburi I, Ruggiero C, Maggolini M, Andò S, et al. 17 β -Estradiol activates GPER- and ESR1-dependent pathways inducing apoptosis in GC-2 cells, a mouse spermatocyte-derived cell line. *Mol Cell Endocrinol* 2012;355:49–59.
- De Marco P, Bartella V, Vivacqua A, Lappano R, Santolla MF, Morcavallo A, et al. Insulin-like growth factor-I regulates GPER expression and function in cancer cells. *Oncogene* 2013;32:678–88.
- Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologa CG, et al. Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. *J Steroid Biochem Mol Biol* 2011;127:358–66.
- Endo Y, Deonauth K, Prahalad P, Hoxter B, Zhu Y, Byers SW. Role of Sox-9, ER81 and VE-cadherin in retinoic acid-mediated trans-differentiation of breast cancer cells. *PLoS ONE* 2008;3:e2714.
- Filice E, Recchia AG, Pellegrino D, Angelone T, Maggolini M, Cerra MC. A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17 β -estradiol in the male rat. *J Physiol Pharmacol* 2009;60:3–10.
- Grego-Bessa J, Díez J, Timmerman L, de la Pompa JL. Notch and epithelial-mesenchyme transition in development and tumor progression: another turn of the screw. *Cell Cycle* 2004;3:718–21.
- Guo S, Liu M, Gonzalez-Perez RR. Role of Notch and its oncogenic signaling crosstalk in breast cancer. *Biochim Biophys Acta* 2011;15:197–213.
- Hiraguri S, Godfrey T, Nakamura H, Graff J, Collins C, Shayesteh L, et al. Mechanisms of inactivation of E-cadherin in breast cancer cell lines. *Cancer Res* 1998;58:1972–7.
- Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. *J Cell Physiol* 2003;194:237–55.
- Kalluri R, Zeisberg M. Fibroblasts in cancer. *Nat Rev Cancer* 2006;6:392–401.
- Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. *Cell* 2009;137:216–33.

- Lappano R, De Marco P, De Francesco EM, Chimento A, Pezzi V, Maggiolini M. Cross-talk between GPER and growth factor signaling. *J Steroid Biochem Mol Biol* 2013;. <http://dx.doi.org/10.1016/j.jsbmb.2013.03.005>.
- Lappano R, Recchia AG, De Francesco EM, Angelone T, Cerra MC, Picard D, et al. The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor α -mediated signaling in cancer cells and in cardiomyocytes. *PLoS ONE* 2011;6:e16631.
- Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, Maggiolini M. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. *Mol Cell Endocrinol* 2010;320:162–70.
- Lappano R, Rosano C, Santolla MF, Pupo M, De Francesco EM, De Marco P, et al. Two novel GPER agonists induce gene expression changes and growth effects in cancer cells. *Curr Cancer Drug Targets* 2012a;12:531–42.
- Lappano R, Santolla MF, Pupo M, Sinicropi MS, Caruso A, Rosano C, et al. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells. *Breast Cancer Res* 2012b;14:R12.
- Liang J, Shang Y. Estrogen and cancer. *Annu Rev Physiol* 2013;75:225–40.
- Madeo A, Maggiolini M. Nuclear alternate estrogen receptor GPR30 mediates 17 β -estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. *Cancer Res* 2010;70:6036–46.
- Madeo A, Vinciguerra M, Lappano R, Galgani M, Gasperi-Campani A, Maggiolini M, et al. c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells. *Oncogene* 2010;29:978–91.
- Maggiolini M, Donzé O, Picard D. A non-radioactive method for inexpensive quantitative RT-PCR. *Biol Chem* 1999;380:695–7.
- Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. *J Endocrinol* 2010;204:105–14.
- Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, et al. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17 β -estradiol and phytoestrogens in breast cancer cells. *J Biol Chem* 2004;279:27008–16.
- Matsuno Y, Coelho AL, Jarai G, Westwick J, Hogaboam CM. Notch signaling mediates TGF- β 1-induced epithelial-mesenchymal transition through the induction of Snai1. *Int J Biochem Cell Biol* 2012;44:776–89.
- Miele L. Notch signaling. *Clin Cancer Res* 2006;12:1074–9.
- Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, et al. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. *Oncogene* 2008;27:5019–32.
- Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. *EMBO J* 2009;28:523–32.
- Panno ML, Salerno M, Pezzi V, Sisci D, Maggiolini M, Mauro L, et al. Effect of oestradiol and insulin on the proliferative pattern and on oestrogen and progesterone receptor contents in MCF-7 cells. *J Cancer Res Clin Oncol* 1996;122:745–9.
- Pupo M, Pisano A, Lappano R, Santolla MF, De Francesco EM, Abonante S, et al. Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts. *Environ Health Perspect* 2012;120:1177–82.
- Pupo M, Vivacqua A, Perrotta I, Pisano A, Aquila S, Abonante S, et al. The nuclear localization signal is required for nuclear GPER translocation and function in breast Cancer-Associated Fibroblasts (CAFs). *Mol Cell Endocrinol* 2013;376:23–32.
- Recchia AG, De Francesco EM, Vivacqua A, Sisci D, Panno ML, Andò S, et al. The G protein-coupled receptor 30 is up-regulated by hypoxia inducible factor-1 α (HIF-1 α) in breast cancer cells and cardiomyocytes. *J Biol Chem* 2011;286:10773–82.
- Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. *Cancer Res* 2005;65:8530–7.
- Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signalling. *Science* 2005;307:1625–30.
- Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. *Cancer Res* 2008a;68:5226–35.
- Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. *Oncogene* 2008b;27:5124–31.
- Rosano C, Lappano R, Santolla MF, Ponassi M, Donadini A, Maggiolini M. Recent advances in the rationale design of GPER ligands. *Curr Med Chem* 2012;19:6199–206.
- Santolla MF, Lappano R, De Marco P, Pupo M, Vivacqua A, Sisci D, et al. GPER mediates the up-regulation of fatty acid synthase (FASN) induced by 17 β -estradiol in cancer cells and cancer-associated fibroblasts (CAFs). *J Biol Chem* 2012;287:43234–45.
- Thiery JP. Epithelial-mesenchymal transitions in tumour progression. *Nat Rev Cancer* 2002;2:442–54.
- Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. *Endocrinology* 2005;146:624–32.
- Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A, et al. 17 β -Estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein coupled-receptor GPR30. *Mol Pharmacol* 2006a;70:1414–23.
- Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Andò S, et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17 β -estradiol and hydroxytamoxifen in endometrial cancer cells. *Mol Endocrinol* 2006b;20:631–46.
- Vivacqua A, Lappano R, De Marco P, Sisci D, Aquila S, De Amicis F, et al. G protein-coupled receptor 30 expression is up-regulated by EGF and TGF α in estrogen receptor alpha-positive cancer cells. *Mol Endocrinol* 2009;23:1815–26.
- Vivacqua A, Romeo E, De Marco P, De Francesco EM, Abonante S, Maggiolini M. GPER mediates the Egr-1 expression induced by 17 β -estradiol and 4-hydroxytamoxifen in breast and endometrial cancer cells. *Breast Cancer Res Treat* 2012;133:1025–35.
- Wang Z, Li Y, Kong D, Sarkar FH. The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. *Curr Drug Targets* 2010;11:745–51.
- Wu L, Griffin JD. Modulation of Notch signaling by mastermind-like (MAML) transcriptional co-activators and their involvement in tumorigenesis. *Semin Cancer Biol* 2004;14:348–56.
- Yin L, Velazquez OC, Liu ZJ. Notch signaling: emerging molecular targets for cancer therapy. *Biochem Pharmacol* 2010;80:690–701.